Virion background and efficiency of virion incorporation determine susceptibility of simian immunodeficiency virus Env-driven viral entry to inhibition by IFITM proteins

Journal of Virology

Volumn 91, Issue 2, 2017, Pages

  Wrensch, Florian ^a   Hoffmann, Markus ^a   Gärtner, Sabine ^a   Nehlmeier, Inga ^a   Winkler, Michael ^a   Pöhlmann, Stefan ^a  

^a GERMAN PRIMATE CENTER   (Germany)

Author keywords

Entry; IFITM; SIV

Indexed keywords

INTERFERON; INTERFERON INDUCED TRANSMEMBRANE PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ARTICLE; CONTROLLED STUDY; EMBRYO; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; HUMAN CELL; INNATE IMMUNITY; LIMIT OF QUANTITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIMIAN IMMUNODEFICIENCY VIRUS; VIRION; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS PARTICLE; VIRUS REPLICATION; ANIMAL; CELL LINE; DISEASE PREDISPOSITION; GENE SILENCING; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HOST PATHOGEN INTERACTION; METABOLISM; PHYSIOLOGY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIROLOGY; VIRUS ASSEMBLY; VIRUS GENOME;

ANIMALS; CELL LINE; DISEASE SUSCEPTIBILITY; GENE KNOCKDOWN TECHNIQUES; GENETIC VECTORS; GENOME, VIRAL; HOST-PATHOGEN INTERACTIONS; HUMANS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSDUCTION, GENETIC; VIRAL ENVELOPE PROTEINS; VIRION; VIRUS ASSEMBLY; VIRUS INTERNALIZATION;

EID: 85008690171     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01488-16     Document Type: Article

References (42)

1. Schneider WM, Chevillotte MD, Rice CM. 2014. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol 32:513-545. https://doi.org/10.1146/annurev-immunol-032713-120231.
2. Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA. 2011. Pattern recognition receptors and the innate immune response to viral infection. Viruses 3:920-940. https://doi.org/10.3390/v3060920.
3. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472:481-485. https://doi.org/10.1038/nature09907.
4. Bailey CC, Zhong G, Huang IC, Farzan M. 2014. IFITM-family proteins: the cell's first line of antiviral defense. Annu Rev Virol 1:261-283. https://doi.org/10.1146/annurev-virology-031413-085537.
5. Everitt AR, Clare S, McDonald JU, Kane L, Harcourt K, Ahras M, Lall A, Hale C, Rodgers A, Young DB, Haque A, Billker O, Tregoning JS, Dougan G, Kellam P. 2013. Defining the range of pathogens susceptible to Ifitm3 restriction using a knockout mouse model. PLoS One 8:e80723. https://doi.org/10.1371/journal.pone.0080723.
6. Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, Ryan BJ, Weyer JL, van der Weyden L, Fikrig E, Adams DJ, Xavier RJ, Farzan M, Elledge SJ. 2009. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 139: 1243-1254. https://doi.org/10.1016/j.cell.2009.12.017.
7. Huang IC, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM, Chiang JJ, Brass AL, Ahmed AA, Chi X, Dong L, Longobardi LE, Boltz D, Kuhn JH, Elledge SJ, Bavari S, Denison MR, Choe H, Farzan M. 2011. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog 7:e1001258. https://doi.org/10.1371/journal.ppat.1001258.
8. Perreira JM, Chin CR, Feeley EM, Brass AL. 2013. IFITMs restrict the replication of multiple pathogenic viruses. J Mol Biol 425:4937-4955. https://doi.org/10.1016/j.jmb.2013.09.024.
9. Smith SE, Gibson MS, Wash RS, Ferrara F, Wright E, Temperton N, Kellam P, Fife M. 2013. Chicken interferon-inducible transmembrane protein 3 restricts influenza viruses and lyssaviruses in vitro. J Virol 87: 12957-12966. https://doi.org/10.1128/JVI.01443-13.
10. Bailey CC, Huang IC, Kam C, Farzan M. 2012. Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog 8:e1002909. https://doi.org/10.1371/journal.ppat.1002909.
11. Lu J, Pan Q, Rong L, He W, Liu SL, Liang C. 2011. The IFITM proteins inhibit HIV-1 infection. J Virol 85:2126-2137. https://doi.org/10.1128/JVI.01531-10.
12. Jiang D, Weidner JM, Qing M, Pan XB, Guo H, Xu C, Zhang X, Birk A, Chang J, Shi PY, Block TM, Guo JT. 2010. Identification of five interferoninduced cellular proteins that inhibit West Nile virus and dengue virus infections. J Virol 84:8332-8341. https://doi.org/10.1128/JVI.02199-09.
13. Desai TM, Marin M, Chin CR, Savidis G, Brass AL, Melikyan GB. 2014. IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion. PLoS Pathog 10: e1004048. https://doi.org/10.1371/journal.ppat.1004048.
14. Li K, Markosyan RM, Zheng YM, Golfetto O, Bungart B, Li M, Ding S, He Y, Liang C, Lee JC, Gratton E, Cohen FS, Liu SL. 2013. IFITM proteins restrict viral membrane hemifusion. PLoS Pathog 9:e1003124. https://doi.org/10.1371/journal.ppat.1003124.
15. John SP, Chin CR, Perreira JM, Feeley EM, Aker AM, Savidis G, Smith SE, Elia AE, Everitt AR, Vora M, Pertel T, Elledge SJ, Kellam P, Brass AL. 2013. The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication. J Virol 87:7837-7852. https://doi.org/10.1128/JVI.00481-13.
16. Amini-Bavil-Olyaee S, Choi YJ, Lee JH, Shi M, Huang IC, Farzan M, Jung JU. 2013. The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe 13:452-464. https://doi.org/10.1016/j.chom.2013.03.006.
17. Qian J, Le DY, Wang Y, Pan Q, Ding S, Zheng YM, Liu SL, Liang C. 2015. Primate lentiviruses are differentially inhibited by interferon-induced transmembrane proteins. Virology 474:10-18. https://doi.org/10.1016/j.virol.2014.10.015.
18. Wilkins J, Zheng YM, Yu J, Liang C, Liu SL. 2016. Nonhuman primate IFITM proteins are potent inhibitors of HIV and SIV. PLoS One 11: e0156739. https://doi.org/10.1371/journal.pone.0156739.
19. Compton AA, Bruel T, Porrot F, Mallet A, Sachse M, Euvrard M, Liang C, Casartelli N, Schwartz O. 2014. IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread. Cell Host Microbe 16:736-747. https://doi.org/10.1016/j.chom.2014.11.001.
20. Tartour K, Appourchaux R, Gaillard J, Nguyen XN, Durand S, Turpin J, Beaumont E, Roch E, Berger G, Mahieux R, Brand D, Roingeard P, Cimarelli A. 2014. IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity. Retrovirology 11:103. https://doi.org/10.1186/s12977-014-0103-y.
21. Yu J, Li M, Wilkins J, Ding S, Swartz TH, Esposito AM, Zheng YM, Freed EO, Liang C, Chen BK, Liu SL. 2015. IFITM proteins restrict HIV-1 infection by antagonizing the envelope glycoprotein. Cell Rep 13:145-156. https://doi.org/10.1016/j.celrep.2015.08.055.
22. Wrensch F, Winkler M, Pöhlmann S. 2014. IFITM proteins inhibit entry driven by the MERS-coronavirus spike protein: evidence for cholesterolindependent mechanisms. Viruses 6:3683-3698. https://doi.org/10.3390/v6093683.
23. Kirchhoff F, Pöhlmann S, Hamacher M, Means RE, Kraus T, Uberla K, Di Marzio P. 1997. Simian immunodeficiency virus variants with differential T-cell and macrophage tropism use CCR5 and an unidentified cofactor expressed in CEMx174 cells for efficient entry. J Virol 71:6509-6516.
24. Weidner JM, Jiang D, Pan XB, Chang J, Block TM, Guo JT. 2010. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol 84: 12646-12657. https://doi.org/10.1128/JVI.01328-10.
25. Yuste E, Reeves JD, Doms RW, Desrosiers RC. 2004. Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity. J Virol 78:6775-6785. https://doi.org/10.1128/JVI.78.13.6775-6785.2004.
26. Del Prete GQ, Scarlotta M, Newman L, Reid C, Parodi LM, Roser JD, Oswald K, Marx PA, Miller CJ, Desrosiers RC, Barouch DH, Pal R, Piatak M, Jr, Chertova E, Giavedoni LD, O'Connor DH, Lifson JD, Keele BF. 2013. Comparative characterization of transfection-and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies. J Virol 87:4584-4595. https://doi.org/10.1128/JVI.03507-12.
27. Wrensch F, Karsten CB, Gnirss K, Hoffmann M, Lu K, Takada A, Winkler M, Simmons G, Pöhlmann S. 2015. Interferon-induced transmembrane protein-mediated inhibition of host cell entry of ebolaviruses. J Infect Dis 212(Suppl 2):S210-S218. https://doi.org/10.1093/infdis/jiv255.
28. Chackerian B, Haigwood NL, Overbaugh J. 1995. Characterization of a CD4-expressing macaque cell line that can detect virus after a single replication cycle and can be infected by diverse simian immunodeficiency virus isolates. Virology 213:386-394. https://doi.org/10.1006/viro.1995.0011.
29. Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, Chin CR, Feeley EM, Sims JS, Adams DJ, Wise HM, Kane L, Goulding D, Digard P, Anttila V, Baillie JK, Walsh TS, Hume DA, Palotie A, Xue Y, Colonna V, Tyler-Smith C, Dunning J, Gordon SB, Smyth RL, Openshaw PJ, Dougan G, Brass AL, Kellam P. 2012. IFITM3 restricts the morbidity and mortality associated with influenza. Nature 484:519-523. https://doi.org/10.1038/nature10921.
30. Hanika A, Larisch B, Steinmann E, Schwegmann-Wessels C, Herrler G, Zimmer G. 2005. Use of influenza C virus glycoprotein HEF for generation of vesicular stomatitis virus pseudotypes. J Gen Virol 86:1455-1465. https://doi.org/10.1099/vir.0.80788-0.
31. Eckert N, Wrensch F, Gartner S, Palanisamy N, Goedecke U, Jager N, Pöhlmann S, Winkler M. 2014. Influenza A virus encoding secreted Gaussia luciferase as useful tool to analyze viral replication and its inhibition by antiviral compounds and cellular proteins. PLoS One 9:e97695. https://doi.org/10.1371/journal.pone.0097695.
32. Simmons G, Reeves JD, Grogan CC, Vandenberghe LH, Baribaud F, Whitbeck JC, Burke E, Buchmeier MJ, Soilleux EJ, Riley JL, Doms RW, Bates P, Pöhlmann S. 2003. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 305:115-123. https://doi.org/10.1006/viro.2002.1730.
33. Chaipan C, Kobasa D, Bertram S, Glowacka I, Steffen I, Tsegaye TS, Takeda M, Bugge TH, Kim S, Park Y, Marzi A, Pöhlmann S. 2009. Proteolytic activation of the 1918 influenza virus hemagglutinin. J Virol 83: 3200-3211. https://doi.org/10.1128/JVI.02205-08.
34. Hoffmann M, Gonzalez HM, Berger E, Marzi A, Pöhlmann S. 2016. The glycoproteins of all filovirus species use the same host factors for entry into bat and human cells but entry efficiency is species dependent. PLoS One 11:e0149651. https://doi.org/10.1371/journal.pone.0149651.
35. Hoffmann M, Kruger N, Zmora P, Wrensch F, Herrler G, Pöhlmann S. 2016 The hemagglutinin of bat-associated influenza viruses is activated by TMPRSS2 for pH-dependent entry into bat but not human cells. PLoS One 11:e0152134. https://doi.org/10.1371/journal.pone.0152134.
36. Yadav SS, Wilson SJ, Bieniasz PD. 2012. A facile quantitative assay for viral particle genesis reveals cooperativity in virion assembly and saturation of an antiviral protein. Virology 429:155-162. https://doi.org/10.1016/j.virol.2012.04.008.
37. Burkard C, Bloyet LM, Wicht O, van Kuppeveld FJ, Rottier PJ, de Haan CA, Bosch BJ. 2014. Dissecting virus entry: replication-independent analysis of virus binding, internalization, and penetration using minimal complementation of beta-galactosidase. PLoS One 9:e101762. https://doi.org/10.1371/journal.pone.0101762.
38. Berger Rentsch M, Zimmer G. 2011. A vesicular stomatitis virus repliconbased bioassay for the rapid and sensitive determination of multispecies type I interferon. PLoS One 6:e25858. https://doi.org/10.1371/journal.pone.0025858.
39. Hoffmann M, Muller MA, Drexler JF, Glende J, Erdt M, Gutzkow T, Losemann C, Binger T, Deng H, Schwegmann-Wessels C, Esser KH, Drosten C, Herrler G. 2013. Differential sensitivity of bat cells to infection by enveloped RNA viruses: coronaviruses, paramyxoviruses, filoviruses, and influenza viruses. PLoS One 8:e72942. https://doi.org/10.1371/journal.pone.0072942.
40. Kühl A, Hoffmann M, Müller MA, Munster VJ, Gnirss K, Kiene M, Tsegaye TS, Behrens G, Herrler G, Feldmann H, Drosten C, Pöhlmann S. 2011. Comparative analysis of Ebola virus glycoprotein interactions with human and bat cells. J Infect Dis 204(Suppl 3):S840-S849. https://doi.org/10.1093/infdis/jir306.
41. O'Doherty U, Swiggard WJ, Malim MH. 2000. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 74:10074-10080. https://doi.org/10.1128/JVI.74.21.10074-10080.2000.
42. Edinger AL, Ahuja M, Sung T, Baxter KC, Haggarty B, Doms RW, Hoxie JA. 2000 Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein. J Virol 74:7922-7935. https://doi.org/10.1128/JVI.74.17.7922-7935.2000.